Which Weight Loss Injection Is the Safest? What UK Evidence Actually Shows

Why 'safest' isn't a single answer (and what the decision actually hinges on

A question our prescribers hear most weeks is some version of: "Which injection is the safer one?" It's a completely reasonable thing to ask, and the honest answer is that both Mounjaro and Wegovy have robust safety records from large-scale trials) SURMOUNT-1 for tirzepatide and STEP 1 for semaglutide, both published in the New England Journal of Medicine, together involved thousands of adults across multiple years. No serious safety difference between the two has been established in head-to-head data. What differs is the side-effect profile in individual people, and that depends on your existing health conditions, other medicines you take, and how your body responds at each dose step.

Neither medicine is licensed or appropriate for everyone. History of medullary thyroid carcinoma, certain gastrointestinal conditions, and a personal or family history of MEN2 are among the contraindications your prescriber screens for. If you are pregnant, breastfeeding or trying to conceive, neither injection is recommended. The same applies to under-18s. The prescriber's job is to weigh all of this before a single pen is dispensed, which is why clinical assessment isn't a box-ticking formality.

If you want a fuller comparison of how the two medicines stack up on results and tolerability, the best weight loss injection guide covers the head-to-head trial data in detail.

Side effects: what both injections share, and where they differ

The side-effect profiles of Mounjaro and Wegovy overlap considerably because both slow gastric emptying and reduce appetite through gut-hormone pathways. Nausea is the most commonly reported effect with each, typically peaking in the first few days after starting or stepping up a dose, then easing as the body adjusts. Constipation, loose stools, reflux and fatigue are also reported with both. For most people these effects are mild to moderate and settle within a couple of weeks, though that settling period can feel significant in the moment.

The MHRA's Yellow Card scheme allows patients and clinicians to report suspected side effects, and this data actively shapes ongoing safety guidance. If you experience severe, persistent abdominal pain (particularly pain that radiates toward your back) seek medical help promptly rather than waiting for a scheduled review. That pattern can be associated with acute pancreatitis, which the MHRA flagged specifically in its January 2026 Drug Safety Update for GLP-1 medicines.

One practical difference: Mounjaro activates both GIP and GLP-1 receptors, while Wegovy acts on GLP-1 alone. Whether that dual action changes the tolerability picture for a specific person isn't predictable in advance, it's one of the things a prescriber considers alongside your personal history. If you're based in Hull and want to explore your options locally, our weight loss injections Hull page explains what's available and how the clinical process works in your area. You can read more about the injection options available in the UK on the weight loss injections overview page.

The supply-chain safety question most people overlook

Clinical safety and supply-chain safety are two different things, and both matter. The MHRA has warned publicly about counterfeit weight loss pens sold through social media and unverified websites, and enforcement operations in 2025 recovered approximately 20 million doses of illegally traded weight management medicines, worth around £45 million. Fake pens have been found to contain insulin, a life-threatening substitution. The cheapest listings are sometimes the most dangerous ones, precisely because sellers without a pharmacy registration can undercut legitimate supply.

The safe route in the UK is through a pharmacy you can verify on the GPhC pharmacy register. Any legitimate provider will require a clinical consultation, confirm your identity, and issue a prescription before dispensing. Sellers offering these medicines without a prescription, or via discount codes from unverified sources, should be treated as a red flag regardless of price. The safest weight loss injection is always one sourced from a regulated, verifiable pharmacy following a proper clinical assessment.

At nume, our GPhC-registered pharmacy (premises registration 9012878, verifiable at pharmacyregulation.org) dispenses only through the licensed UK supply chain. Every consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers, not software. For more on what the clinical process involves, the about us page sets it out plainly.

What makes a weight loss injection programme safe in practice

The medicine itself is only part of the safety picture. How treatment is monitored, titrated and supported over time matters just as much. Both Mounjaro and Wegovy start at a low dose (2.5mg for tirzepatide, 0.25mg for semaglutide) because beginning gently reduces the severity of early side effects and gives the body time to adapt before moving higher. Skipping steps or pushing doses faster than the licensed schedule risks amplifying side effects without adding meaningful benefit. Your prescriber sets the pace; the Patient Information Leaflet and the NHS medicines guidance for tirzepatide are the references for what to expect at each stage.

Ongoing clinical review is equally important. Weight, tolerability and any new symptoms should be assessed before each dose change. At a regulated service, this review happens before every repeat, it's not a one-time gate. If you're thinking about how treatment fits your personal situation, the which injection is best for me page walks through the personal factors prescribers weigh up.

The free consultation at nume is the starting point: a same-day clinical review by a GPhC-registered prescriber who can assess which medicine, if either, is appropriate for you.